PROTAGENIC THERAPEUTICS (OTCMKTS:PTIX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation
FD.
On May 26, 2017, Protagenic Therapeutics, Inc. (the Company)
issued a letter to its stockholders reporting on the Companys
developmental progress toward filing an FDA Investigational New
Drug (IND) application for its prospective investigation new drug
application in 2018. The stockholder letter is furnished as
Exhibit 99.1 hereto.
The information in this Form 8-K (including the Exhibit) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by referenced in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific referenced in such a filing.
Item9.01.Financial Statements and
Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
Stockholder letter issued on May 26, 2017. |
About PROTAGENIC THERAPEUTICS (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue. PROTAGENIC THERAPEUTICS (OTCMKTS:PTIX) Recent Trading Information
PROTAGENIC THERAPEUTICS (OTCMKTS:PTIX) closed its last trading session 00.00 at 2.00 with 201 shares trading hands.
